Debiopharm and ThinkingNodeLife.ai Forge a Strategic Partnership to Propel Cancer Drug Development with AI Digital Cell Clones
Digital Health Global
JANUARY 10, 2024
Key Highlights of the Partnership: 1) Expanding Indications : The partnership will harness TNL’s AI Digital Cells Lab platform to explore additional indications for one of Debiopharm’s cancer drugs. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.
Let's personalize your content